Association of CD14 gene -260 C>T and -561 C>T polymorphisms with cancer susceptibility: a meta-analysis.
Two polymorphisms, -260 C>T (rs2569190) and -561 C>T (rs5744455), in the CD14 gene have been implicated in susceptibility to cancer. However, the results remain inconclusive. To confirm the function of these two polymorphisms on susceptibility of cancer, we carried out the current meta-analysis. We collected eligible studies from databases including PubMed, EMBASE, CNKI, Wanfang, and VIP (Weipu). We used logistic regression calculation to compute odds ratios (ORs) and 95% confidence intervals (CIs). After strict selection, 24 studies with 5854 cases and 10339 controls for -260 C>T and 7 studies with 1809 cases and 7289 controls for -561 C>T were finally enlisted into our analysis reference material. Pool results revealed that neither -260 C>T nor -561 C>T was found to have any association with overall cancer susceptibility. Nevertheless, when stratified by cancer type, we detected a decreased risk associated with other cancers in heterozygous model (OR=0.69, 95% CI=0.51-0.93, P=0.014) and dominant model (OR=0.70, 95% CI=0.53-0.93, P=0.012) for -561 C>T. An increased risk was found in other cancers under allele model (OR=1.29, 95% CI=1.03-1.62, P=0.026), in laryngeal cancer under dominant model (OR=1.38, 95% CI=1.11-1.71, P=0.003), and in score ≤9 under recessive model (OR=1.45, 95% CI=1.09-1.91, P=0.009) for -561 C>T. Herein, we came with the conclusion that CD14-260 C>T and -561 C>T polymorphisms might not be associated with overall cancer risk. Further studies will be encouraged to ascertain this conclusion.